Clinical trial · Observational
Relation Between Tumor-draining Lymph Nodes Metastasis Pattern and Non-small Cell Lung Cancer Neoadjuvant Immunotherapy Effectiveness
Relation Between Tumor-draining Lymph Nodes Metastasis Pattern and Non-small Cell Lung Cancer Neoadjuvant Immunotherapy Effectiveness: A Retrospective Multi-institutional Cohort Analysis
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this retrospective cohort analysis is to discover the impact of the involvement extent of tumor-draining lymph nodes (TDLNs) in patients who received neoadjuvant immunochemotherapy. The main question it aims to answer is the role of TDLN in the prediction of treatment effectiveness. Researches will compare tumor-draining lymph nodes metastasis (mTDLNs) group and non-draining lymph nodes metastasis (mNDLNs) group to see whether different metastatic patterns of mediastinal lymph nodes can indicate the treatment effectiveness.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Immunotherapy | Drug | Immunotherapy | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- Neoadjuvant immunochemotherapy NSCLC group
- description
- NSCLC patients who received neoadjuvant immunochemotherapy and underwent surgery.
- interventionNames
- Drug: Immunotherapy
Primary outcomes (1)
- measure
- Complete pathologic response
- timeFrame
- through study completion, an average of 3 months
- description
- Tumors with 0% viable tumor cells
Secondary outcomes (2)
- measure
- Major pathologic response
- timeFrame
- through study completion, an average of 3 months
- description
- Tumors with ≤10% viable tumor cells
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * pathologically-confirmed diagnosis of NSCLC by pretreatment biopsy * clinically staged as T1-4N0-2M0 * having undergo neoadjuvant chemoimmunotherapy * the agents of immune checkpoint inhibitors (ICIs) belong to PD-1/L1 inhibitors * having undergo surgery with lymph nodes (LNs) dissection * having postoperative pathology reports with evaluation of primary tumor and LNs response * having accessible pretreatment and preoperative radiology examinations imaging or reports Exclusion Criteria: * using PD-1/L1 inhibitors in the phase of clinical trials * the agents of neoadjuvant therapy including angiogenesis inhibitors * having undergone radiotherapy to treat primary tumor or metastatic LNs before surgery
References
Publications (2)
- RESULTRahim MK, Okholm TLH, Jones KB, McCarthy EE, Liu CC, Yee JL, Tamaki SJ, Marquez DM, Tenvooren I, Wai K, Cheung A, Davidson BR, Johri V, Samad B, O'Gorman WE, Krummel MF, van Zante A, Combes AJ, Angelo M, Fong L, Algazi AP, Ha P, Spitzer MH. Dynamic CD8+ T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes. Cell. 2023 Mar 16;186(6):1127-1143.e18. doi: 10.1016/j.cell.2023.02.021. PMID 36931243
- RESULTProkhnevska N, Cardenas MA, Valanparambil RM, Sobierajska E, Barwick BG, Jansen C, Reyes Moon A, Gregorova P, delBalzo L, Greenwald R, Bilen MA, Alemozaffar M, Joshi S, Cimmino C, Larsen C, Master V, Sanda M, Kissick H. CD8+ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor. Immunity. 2023 Jan 10;56(1):107-124.e5. doi: 10.1016/j.immuni.2022.12.002. Epub 2022 Dec 28. PMID 36580918